Smith Darren Charlton's Form 4 filing
Telix Pharmaceuticals Ltd (TLX) · filed Sep 14, 2026
- Accession no.
- 0001628280-26-061944
- Filed
- Sep 14, 2026, 7:20 PM ET
- Trade date
- Sep 7, 2026
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $20.0K. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith Darren CharltonCIK 0002122447 | Officer (Group Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | Ordinary Shares | PPurchaseAcquired | +2,071 | $9.66 | +$19,997.58 | 13,992 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.